EXTON, Pa., Feb. 11, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq : VPHM ) today announced that Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the 2013 Leerink Swann Global Healthcare Conference at 11:30 AM ET on Thursday, February 14, 2013. The conference is being held at the Waldorf Astoria in New York City.
ViroPharma also announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Cowen and Company 33rd Annual Healthcare Conference at 8:00 AM ET on Wednesday, March 6, 2013. The conference is being held at the Boston Marriott Copley Place.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated